SUNITINIB相关论文
...
Correlation of KIT mutational status with clinical benefit in a patient with gastrointestinal stroma
Objective GISTs are a form of sarcoma and the most common gastrointestinal mesenchymal tumors(Miettinen 2008; Corless 20......
Conditional disease-free survival in high risk localized renal cell carcinoma treated with or withou
...
Multidrug resistant recurrent/metastatic intestinal GIST expressing KIT exon 9/17 mutation benefited
Objectives We present here a 60-year-old man with recurrent/metastatic intestinal GIST expressing KIT exon 9/17 mutation......
Tyrosine kinase inhibitor sunitinib therapy is effective in treatment of bone metastasis from cancer
Bone metastasis from cancer of unknown primary(BMCUP)brings poor survival prognosis and its management remains controver......
Severe adverse drug reactions/hyperhydrosis induced by Sunitinib misuse in a nephrectomy patient:A c
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor licensed for the treatment of renal cell carcinoma both in......
Objective: As a potent angiogenesis inhibitor, Sunitinib has shown good response in clinic.However, severe toxic side ef......
Sunitinib,which is a multitargeted tyrosine-kinase inhibitor,exhibits antiangiogenic and antitumor activity.and extends ......
The development of new cancer chemotherapies has been improving the prognosis of patients with cancer.Indeed, age-standa......
...
Evaluation of efficacy and safety of sunitinib regimen in 22 patients with metastatic renal cell car
...
Efficacy of sunitinib in patients with metastatic renal cell carcinoma:initial experience in two Chi
...
This research investigated a novel folic acid(FA)-modified zirconium core metal-organic framework(MOF)Uio-66 as a nanoca......
目的：探讨舒尼替尼相关性血液学不良反应与晚期肾细胞癌的预后关系。方法：选取2010年6月-2014年6月上海长征医院泌尿外科收治的56例......
1例52岁男性肾透明细胞癌患者右肾切除术后1个月开始接受舒尼替尼靶向治疗(舒尼替尼50 mg口服，1次/d，连续4周，间隔2周，6周为1个周期)。......
舒尼替尼是一种靶向多种受体酪氨酸激酶(RTK)抑制剂，用于治疗晚期肾细胞癌、伊马替尼不耐受和伊马替尼耐药的难治性胃肠道间质瘤。......
狂犬病(Rabies)是由狂犬病病毒(Rabies virus,RABV)感染引起的,是一种被忽视的重要人兽共患病。经RABV感染出现临床症状后,死亡率......
目的:探究肾癌转移部位在接受舒尼替尼靶向治疗晚期肾细胞癌患者预后的相关性.方法:回顾性分析2008年3月～2014年2月在我院接受靶向......
目的:探讨单中心14例晚期肾癌患者应用舒尼替尼4/2方案行新辅助分子靶向治疗的临床疗效及经验.方法:回顾性分析2010年12月～2014年12......
舒尼替尼(sunitinib,SUN)是一种多靶点酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI),在使用过程中会由于引发缺氧而增加肿瘤......
近年来载药微球在栓塞治疗中引起了广泛关注.本研究采用反相悬浮聚合法制备了用于栓塞的聚乙烯醇/丙烯酸微球,首先筛分出粒径在100......
本研究建立并验证了一种灵敏、快速、简单的液质联用方法,用于同时测定BABL/c裸鼠血浆中舒尼替尼及其活性代谢产物SU12662的药物浓......
乳腺癌是女性最易罹患的疾病,而肿瘤多药耐药性通常是化疗失败的主要原因.本研究以培美曲塞(PMT)和DSPE-PEG2000-NH2为原料合成了......
本研究建立和验证了测定家兔血浆中舒尼替尼含量的液相色谱串联质谱法(LC-MS/MS).含舒尼替尼的血浆样品经乙腈沉淀蛋白质后,用Zorb......
鸟嘌呤富集序列可形成稳定的一种核酸二级结构,G-四链体,其广泛存在于基因组中.稳定G-四链体的化学小分子可以抑制肿瘤细胞增长,然......
舒尼替尼(sunitinib)为一种口服多靶点酪氨酸激酶抑制剂,其作用靶点包括血小板衍生生长因子受体(PDGFRα、PDGFRβ)、血管内皮生长......
目的:构建胃肠道间质瘤耐药细胞模型GIST882-Rs。方法:通过间歇浓度梯度倍增法针对胃肠道间质瘤细胞株GIST882进行体外诱导，使其对S......
...
,PK/PD modeling based on NO-ET homeostasis for improving management of sunitinib-induced hypertensio
Sunitinib is an oral small molecule multitargeted tyrosine kinase inhibitor,which is currently used to treat severe canc......
研究背景及目的：肿瘤细胞对化疗药物产生原发和继发耐药是肿瘤有效治疗的主要障碍。多种机制参与肿瘤细胞耐药性的形成，包括药物作用......
目的：研究受体酪氨酸激酶抑制剂sunitinib对EGF诱导的HaCaT细胞(HaCaT/E)增殖与凋亡的影响及内在机制。方法：1.采用细胞计数的方式检......
舒尼替尼是一种口服的多靶点酪氨酸激酶抑制剂,具有抗血管生成和抑制肿瘤增殖的作用.与IFN-α相比,舒尼替尼明显提高了转移性肾癌(......
Curcumin based combination therapy for anti-breast cancer: from in vitro drug screening to in vivo e
该文从挂篮荷载计算、施工流程、支座及临时固结施工、挂篮安装及试验、合拢段施工、模板制作安装、钢筋安装、混凝土的浇筑及养生......
Perforation of the colon by invading recurrent gastrointestinal stromal tumors during sunitinib trea
该文从挂篮荷载计算、施工流程、支座及临时固结施工、挂篮安装及试验、合拢段施工、模板制作安装、钢筋安装、混凝土的浇筑及养生......
舒尼替尼是一种口服多靶点受体酪氨酸激酶抑制剂,用于治疗转移性肾细胞癌和伊马替尼治疗失败或不耐受的转移性胃肠道间质瘤。舒尼......
目的建立HPLC-MS/MS法同时测定人血浆中舒尼替尼及其活性代谢产物N-去乙基舒尼替尼(SU12662)的浓度。方法以氘代舒尼替尼为内标,用......
舒尼替尼对肾癌的分子靶向治疗虽然已经取得确切的临床疗效,但并非所有患者都能从中获益。单核苷酸多态性(SNP)可能是导致有些患者......
...
Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochro
Sporadic malignant pheochromocytoma,a rare disease with poor prognosis,is always difficult to treat due in part to lack ......
Evaluation of efficacy and safety of sunitinib regimen in 22 patients with metastatic renal cell car
Background Sunitinib has been proved an effective new option for treatment of metastatic renal cell carcinoma (mRCC).Ana......
Efficacy of sunitinib in patients with metastatic renal cell carcinoma:initial experience in two Chi
Background The advent of targeted therapy has proved a milestone in the history of metastatic renal cell carcinoma treat......
Sunitinib malate is one of the multitargeted tyrosine kinase inhibitor, which are being used in clinic.It can inhibit mo......
Nasal metastases from renal cell carcinoma are associated with Memorial Sloan-Kettering Cancer Cente
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7......
Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line th
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7......
Objective To investigate the growth-inhibitory effect of sunitinib malate on human bladder transitional cell carcinoma(T......
Sunitinib effectiveness and safety as ifrst line treatment in metastatic renal cell carcinoma, in th
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7......
【摘要】 目的 提高胃肠道间质瘤(GIST)的诊治水平。方法 分析近10年来我院收治的36名GIST患者,总结GIST的诊治结果。结果 36例均......
舒尼替尼是一个小分子多靶点酪氨酸激酶抑制剂,可抑制多个与肿瘤生长和血管生成相关的受体酪氨酸激酶.2006年被FDA批准用于不能耐......
Sunitinib malate is one of the multitargeted tyrosine kinase inhibitor, which are being used in clinic.It can inhibit mo......
